-+ 0.00%
-+ 0.00%
-+ 0.00%

Tenon Medical Completes First Procedures Using New SImmetry+ SI Joint Fusion System

Benzinga·12/04/2025 13:37:55
语音播报

~ Procedures Completed in Various Spine Centers of Excellence Throughout the Country Including Florida, Arizona, Ohio, and Texas ~

~ SImmetry+ combines 3D-printed titanium implants, a robust joint decorticator, and a streamlined bone graft delivery system to offer treatment solutions aligned with established fusion principles ~

~ Immediate revenue impact opportunity while significantly advancing Tenon's competitive position in redefining SI joint fusion with a multi-approach portfolio in rapidly expanding sacro-pelvic market ~

LOS GATOS, CA / ACCESS Newswire / December 4, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today announced the completion of the first clinical procedures utilizing the Company's new SImmetry+ SI Joint Fusion System. Ali Araghi, DO, Orthopedic Spine Surgeon in Phoenix, Arizona, Brian Fiani, DO Board Certified Neurosurgeon in Tampa, FL., Kraig Kristof, MD, Orthopedic Spine Surgeon in Toledo, OH., and Sunil Panchal, MD Interventional Pain physician in Tampa, FL. were among the first physicians to successfully implant the SImmetry+ system in patients diagnosed with sacroiliac joint dysfunction.

The SImmetry+ SI Joint Fusion System is a next-generation, minimally invasive lateral access solution that incorporates well-established orthopedic fusion principles-including joint decortication, bone graft placement, and rigid fixation-with the goal of achieving a true biological fusion across the SI joint. The system features 3D-printed titanium implants engineered to effectively stabilize the SI Joint by incorporating a self-drilling, self-tapping, and self-harvesting design to streamline implantation and enhance bone preparation and fusion. The system is cleared for use with one to three implants, allowing physicians flexibility based on patient anatomy and pathology.

Initial physician use of SImmetry+ is currently underway through a controlled, early-access rollout with a select group of experienced SI fusion physicians as listed above. These early adopters will provide important procedural and clinical feedback on the implant design, technique, and instrumentation to support a broader commercial launch readiness. Additional alpha cases are currently being scheduled at multiple Centers of Excellence across the United States.

Clinical evidence supporting the SImmetry+ system includes 12-month outcomes from the EvoluSIon study, published in the International Journal of Spine Surgery. Among 250 treated patients, the procedure demonstrated a strong safety profile and resulted in meaningful reductions in pain and improvement in quality-of-life measures. Patients also experienced a 57.1% decrease in pre-operative opioid use and at 12 months, 68.7% of patients showed radiographic fusion of the SI joint confirmed by computed tomography (CT) and independently reviewed by a trained radiologist.